Evidence-Based Botanical Research: Applications and Challenges

Hematology/Oncology Clinics of North America

Volumn 22, Issue 4, 2008, Pages 661-670

  Yeung, K Simon ^a   Gubili, Jyothirmai ^a   Cassileth, Barrie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHARANTHUS ROSEUS EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; PLACEBO; SILYBUM MARIANUM EXTRACT; TAXUS BREVIFOLIA EXTRACT; VISCUM ALBUM EXTRACT;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ETHNOBOTANY; EVIDENCE BASED MEDICINE; HERBAL MEDICINE; HUMAN; NEOPLASM; NONHUMAN; NUTRITIONAL VALUE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TRADITIONAL MEDICINE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; ETHNOBOTANY; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 47149118700     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.04.007     Document Type: Review

References (35)

1. Kelly J.P., Kaufman D.W., Kelley K., et al. Use of herbal/natural supplements according to racial/ethnic group. J Altern Complement Med 12 6 (2006) 555-561
2. Correa-Velez I., Clavarino A., and Eastwood H. Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med 8 5 (2005) 953-961
3. Gupta D., Lis C.G., Birdsall T.C., et al. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 13 11 (2005) 912-919
4. Evans M., Shaw A., Thompson E.A., et al. Decisions to use complementary and alternative medicine (CAM) by male cancer patients: information-seeking roles and types of evidence used. BMC Complement Altern Med 7 (2007) 25
5. Verhoef M.J., Balneaves L.G., Boon H.S., et al. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 4 4 (2005) 274-286
6. Meijerman I., Beijnen J.H., and Schellens J.H. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11 7 (2006) 742-752
7. Yeung K.S., and Gubili J. Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol 5 3 (2007) 113-117
8. Linde K., Mulrow C.D., Berner M., et al. St John's wort for depression. Cochrane Database Syst Rev 2 (2005) CD000448
9. Mathijssen R.H., Verweij J., de Bruijn P., et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94 16 (2002) 1247-1249
10. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (2005), People's Medical Publishing House, Beijing (China)
11. In: Blumenthal M. (Ed). The Complete German Commission E Monographs-Therapeutic Guide to Herbal Medicines (1998), Integrative Medicine Communications, Boston
12. Ekins S., Mestres J., and Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 152 1 (2007) 21-37
13. NCI/NIH. Developmental therapeutics program. Available at:. http://dtp.nci.nih.gov/branches/npb/repository.html Accessed January 29, 2008
14. NCI/NIH. Natural products branch. Available at:. http://dtp.nci.nih.gov/screening.html Accessed January 29, 2008
15. Cragg G.M., Boyd M.R., Cardellina II J.H., et al. Ethnobotany and drug discovery: the experience of the US National Cancer Institute. Ciba Found Symp 185 (1994) 178-190 [discussion: 190-76]
16. WHO. General guidelines for methodologies on research and evaluation of traditional medicine. Available at:. http://whqlibdoc.who.int/hq/2000/WHO_EDM_TRM_2000.1.pdf Accessed January 29, 2008
17. Hishida I., Nanba H., and Kuroda H. Antitumor activity exhibited by orally administered extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 36 5 (1988) 1819-1827
18. Vickers A.J. How to design a phase I trial of an anticancer botanical. J Soc Integr Oncol 4 1 (2006) 46-51
19. Daugherty C.K., Ratain M.J., Emanuel E.J., et al. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol 26 8 (2008) 1371-1378
20. Newton K.M., Reed S.D., LaCroix A.Z., et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 145 12 (2006) 869-879
21. Pockaj B.A., Gallagher J.G., Loprinzi C.L., et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 24 18 (2006) 2836-2841
22. USDA. Fresh product grading and quality certification. Available at:. http://www.ams.usda.gov/fv/fpbgapghp.htm Accessed January 29, 2008
23. WHO. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Available at:. http://whqlibdoc.who.int/publications/2003/9241546271.pdf Accessed January 29, 2008
24. FDA. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at:. http://www.fda.gov/OHRMS/DOCKETS/98fr/07-3039.pdf Accessed February 27, 2008
25. NCCAM. Interim applicant guidance: product quality: biologically active agents used in complementary and alternative medicine (CAM) and placebo materials. Available at:. http://grants.nih.gov/grants/guide/notice-files/NOT-AT-05-004.html Accessed January 29, 2008
26. CDER. Guidance for industry-botanical drug products. Available at:. http://www.fda.gov/cder/index.html Accessed January 29, 2008
27. Gagnier J.J., Boon H., Rochon P., et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 144 5 (2006) 364-367
28. CDER. Guidance for industry: formal meetings with sponsors and applicants for PDUFA products. Available at:. http://www.fda.gov/cder/guidance/2125fnl.pdf Accessed January 29, 2008
29. CDER. Botanical review team. Available at:. http://www.fda.gov/cder/index.html Accessed January 29, 2008
30. CDER. Guidance documents. Available at:. www.fda.gov/cder/guidance/index.htm Accessed January 29, 2008
31. CDER. Guidance for industry-botanical drug products. Available at:. http://www.fda.gov/cder/guidance/4592fnl.pdf Accessed January 29, 2008
32. CDER. Drug applications. Available at:. http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm Accessed January 29, 2008
33. CDER. Drug approval application process. Available at:. http://www.fda.gov/cder/regulatory/applications/default.htm Accessed January 29, 2008
34. NCCAM. NCCAM's research centers program. Available at:. http://nccam.nih.gov/training/centers/ Accessed January 31, 2008
35. NIH. Clinical trials. Available at:. http://www.clinicaltrials.gov/ Accessed January 29, 2008